A study to determine the concordance of key actionable genomic alterations as assessed in tumor tissue and plasma from patients with non small cell lung carcinoma (NSCLC)
Description: Assess concordance of genomic alterations in EGFR detected in plasma versus tumor tissue in stage IV non squamous NSCLC patients who are newly diagnosed or progressing on treatment.
Measure: EGFR Detected in Plasma Versus Tumor Tissue in Stage IV Non Squamous NSCLC Patients Who Are Newly Diagnosed or Progressing on Treatment Time: Tumor tissue testing to plasma testingOther
There is one SNP
Characterize the Detection of EGFR T790M Alterations in Plasma in Patients Progressing on EGFR Targeting Therapy (Erlotinib, Gefitinib, Afatinib).. null. --- T790M ---